1 Like
Photocure Partner Asieris presented clinical trial and real-world data on Hexvix in China at ASCO GU 2024
18 Likes
Tar det med på fundamentale forhold også:
New Photocure White Paper addressing Inequality in Bladder Cancer Care and the importance of Real World Evidence
This new White Paper discusses how real world evidence and patient registries can play a part in supporting healthcare equality. It looks at how Photocure supports researchers with data, and at uncovering disparities in bladder cancer care and outcomes through findings reported from several recent real world bladder cancer databases and studies. Some ethnic groups were found to have poorer bladder cancer outcomes than others. Income also appears to be linked to outcomes. Further research will be needed in order to investigate these disparities as first steps towards greater understanding and more equal bladder cancer care and outcomes for all bladder cancer patients, regardless of background, race or gender.
Read the full white paper online: Addressing inequality in bladder cancer care – Why are there still disparities in bladder cancer care and outcomes?
And how can real world evidence play a part in supporting healthcare equality?
While randomized controlled trials are the gold standard in the assessment of the safety and efficacy of new therapies, disparities may exist between the outcomes we see from clinical trials and what we actually see in clinical practice. Photocure remains committed to bridging the knowledge gap that exists in bladder cancer care. The company has supported and worked closely with several patient registries to benefit from real world data, including setting up its own U.S. “Blue Light Cystoscopy with Cysview” Registry, established by Photocure in 2014 and projected to enroll 4,400 patients.
About Bladder Cancer
Bladder cancer ranks as the 8th most common cancer worldwide – the 5th most common in men – with 1 720 000 prevalent cases (5-year prevalence rate)1a, 573 000 new cases and more than 200 000 deaths in 2020.1b
Approx. 75% of all bladder cancer cases occur in men.1 It has a high recurrence rate with up to 61% in year one and up to 78% over five years.2 Bladder cancer has the highest lifetime treatment costs per patient of all cancers.3
Bladder cancer is a costly, potentially progressive disease for which patients have to undergo multiple cystoscopies due to the high risk of recurrence. There is an urgent need to improve both the diagnosis and the management of bladder cancer for the benefit of patients and healthcare systems alike.
Bladder cancer is classified into two types, non-muscle invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of invasion in the bladder wall. NMIBC remains in the inner layer of cells lining the bladder. These cancers are the most common (75%) of all BC cases and include the subtypes Ta, carcinoma in situ (CIS) and T1 lesions. In MIBC the cancer has grown into deeper layers of the bladder wall. These cancers, including subtypes T2, T3 and T4, are more likely to spread and are harder to treat.4
1 Globocan. a) 5-year prevalence / b) incidence/mortality by population. Available at: https://gco.iarc.fr/today, accessed [January 2022].
2 Babjuk M, et al. Eur Urol. 2019; 76(5): 639-657
3 Sievert KD et al. World J Urol 2009;27:295–300
4 Bladder Cancer. American Cancer Society. https://www.cancer.org/cancer/bladder-cancer.html
6 Likes
Nyhetsinnlegget fra Photocure over her er ett steg på veien for å bli standard of care.
Sitat fra full artikkel:
This is only the beginning as we move towards our goal of equal bladder cancer care and outcomes for all.
Alle skal bli tilbudt den beste behandlingen det må være en menneskerett.
9 Likes
Det mangler jo ikke på positive vinklinger for PHO, men det er jo 13 på dusinet av disse analysene/reportasjene og lite ser ut til å skje…
Det virker å være utrolig tidkrevende å blande seg inn blant SOC, selv om det for oss kan virke som en nobrainer at blått lys også blir SOC.
1 Like
Photocure ASA: Invitation to presentation of 4th quarter and preliminary full year 2023 financial results
2 Likes
Photocure Partner Asieris to present First-ever Results of the international multicenter Phase III clinical Study for Cevira, a non-surgical treatment for cervical HSIL, at the 2024 EUROGIN
9 Likes
Photocure Partner Asieris to Unveil Results of the international multicenter Phase III clinical Study for Cevira, a non-surgical treatment for cervical HSIL, at the 2024 SGO
11 Likes
Photocure Partner Asieris announces positive international Phase III clinical trial results for Cevira and data presentations at the 2024 EUROGIN Congress and SGO Annual Meeting
13 Likes
Her er fra Asieris:
Breakthrough in Treatment of Cervical High-Grade Squamous Intraepithelial Lesion: Release of Positive Results from Multicenter Phase III Global Clinical Study
-
The world’s first non-surgical cervical HSIL treatment validated by an international Phase III clinical study with proven efficacy;
-
The response rate increased by 89.4% compared to the placebo control group, with a low incidence of adverse events;
-
The China new drug application submission is expected in Q2 2024, while ex-China product development is in active progress.
Shanghai, China, March 18, 2024 – Asieris Pharmaceuticals (Stock Code: 688176.SH), a global biopharmaceutical leader in the discovery, development, and commercialization of innovative drugs for genitourinary tumors and related diseases announced that the multicenter Phase III global clinical study data of its non-surgical treatment for cervical HSIL product APL-1702 demonstrated significant efficacy and good safety profile, with new advancements in clearance rate of high-risk HPV16 and/or HPV18. Key data from the study were presented in oral presentations at the 2024 European Research Organization on Genital Infection and Neoplasia (EUROGIN) Congress and the 2024 Society of Gynecologic Oncology (SGO) Annual Meeting.
APL-1702 is a pioneering cold light photodynamic drug-device combination product，used as a non-surgical therapy for treating cervical HSIL. This study is a prospective, randomized, double-blinded, placebo-controlled multicenter Phase III global clinical study designed to evaluate the efficacy and safety of APL-1702 for the treatment of cervical HSIL. Primary endpoint of the study is the proportion of responders at 6 months after the initial treatment. The study is led by Dr. Jinghe Lang, an academician at Peking Union Medical College Hospital, Chinese Academy of Medical Sciences. Response is defined as the conversion of cervical epithelial tissue pathology to normal or the conversion to low-grade squamous intraepithelial lesion (LSIL) while achieving baseline HPV clearance.
According to the study results, between November 2020 and July 2022, a total of 402 eligible patients from various countries including China, Germany, the Netherlands et al. were randomized and enrolled in this study. The response rate in the APL-1702 treatment group showed a statistically significant improvement of 89.4% (41.1% vs. 21.7%, p = 0.0001) compared to that in the placebo control group， indicating a remarkable therapeutic effect. Additionally, APL-1702 showed an improved clearance rate of high-risk HPV16 and/or HPV18, with a 103.9% increase in the APL-1702 treatment group compared to the control group (31.4% vs. 15.4%)1. The incidence of treatment-emergent adverse events (TEAEs) was comparable between the treatment group and the control group, with the majority being mild and self-healing without requiring intervention. The occurrence rates of treatment-related adverse events (TRAEs) and serious adverse events (SAEs) were both low in both groups2.
According to the “Global Cancer Statistics 2020” report, there were 604,127 new cases of cervical cancer in women worldwide in 2020, with 341,831 deaths, ranking it as the fourth most common cancer among women. Cervical cancer incidence ranks second among malignant tumors in Chinese women. According to the “National Cancer Report 2024” released by the National Cancer Center, there were 150,700 new cases of cervical cancer in China in 2022, with 55,700 deaths from cervical cancer.
The main cause of cervical cancer is persistent infection with human papillomavirus (HPV), which leads to precancerous lesions of the cervix. Approximately 25% of individuals with HSIL may progress to invasive cervical cancer within 10 years3 . According to Frost Sullivan analysis, it is projected that by 2030, the number of HSIL patients worldwide and in China will reach 16.6 million and 2.2 million, respectively. With the increasing popularity of dual-cancer screening and cervical cytology tests, more and more patients with cervical precancerous lesions are being detected at early stages before cancer develops, and it is expected that the number of patients will continue to increase.
Women with cervical precancerous lesions have unmet clinical needs for non-surgical therapies. Currently, invasive procedures such as loop electrosurgical excision procedure (LEEP) and cold knife conization remain the primary treatment options for high-grade cervical lesions. However, these surgical treatments are associated with adverse reactions including bleeding, infection, and cervical structural damage, which may lead to complications such as preterm birth and miscarriage. Furthermore, cervical precancerous lesions require long-term monitoring and management because even after surgical treatment, there is a risk of persistent disease or recurrence, with a higher risk of developing cervical cancer compared to the general population (5 times higher risk of invasive cancer within 10 years). Therefore, post-operative follow-up for at least 25 years is necessary. Importantly, if cervical precancerous lesions recur, subsequent surgical interventions become more challenging and carry higher risks, potentially resulting in total hysterectomy. Thus, early surgical intervention increases the difficulty of long-term management. Non-surgical therapies that preserve the intact cervix and avoid or delay cervical trauma are of significant importance for the long-term management of patients with cervical precancerous lesions.
Professor Chen Fei, Chief Physician of the Department of Obstetrics and Gynecology at Peking Union Medical College Hospital, expressed her delight with the research findings, stating, “I am extremely pleased with the results of this study. Treating HSIL serves as the final barrier against cervical cancer. Previous international studies on HSIL have not been successful, but this study, utilizing a multicenter trial design and strict definition of efficacy endpoints, has achieved positive results, which is no easy feat. As a clinician, I have encountered many HSIL patients who desire to preserve their intact cervix while receiving treatment. The emergence of APL-1702 will fulfill the wishes of these patients, allowing them to avoid or delay cervical trauma to the maximum extent possible.”
Professor Qiao Youlin, a member of the WHO Global Expert Group for Cervical Cancer Elimination and a professor at the School of Population Medicine and Public Health at the Chinese Academy of Medical Sciences/Peking Union Medical College, believes that in addition to vaccination and screening, treatment of cervical precancerous lesions is a crucial component of secondary prevention for cervical cancer. However, progress in the field of medication for cervical precancerous lesions has been relatively slow, with high barriers to overcome, and there are currently no approved treatment drugs worldwide. “It is gratifying to see the emergence of innovative products like APL-1702, which simultaneously possess clinical value in addressing the treatment gap, public health value in cervical cancer prevention and control, and social value in promoting fertility-friendly options. This breakthrough will safeguard women’s health and make a positive contribution to the acceleration of the 2030 global and Chinese action plans for cervical cancer elimination”.
Dr. Linda Wu, Chief Development Officer of Asieris Pharmaceuticals, said, “We are extremely proud of the results from the international multicenter Phase III clinical study of APL-1702. The study not only demonstrates remarkable efficacy but also exhibits a favorable safety profile, offering a new powerful artillery for the national cervical cancer prevention and control system. We express our gratitude to all the patients, physicians, and researchers who participated in this study, as their support and dedication have been invaluable. We are actively preparing the new drug application for APL-1702 and plan to submit it in the second quarter of this year. Additionally, we are making significant progress in product development overseas, aiming to bring this innovative treatment to more patients as soon as possible.”
References：
- EUROGIN: Photodynamic therapy with APL-1702 for high-grade squamous intraepithelial lesions (HSIL): results from a randomized phase Ⅲ global study (YHGT-CEV-1/APRICITY)
- SGO: APL-1702 long-term efficacy and safety for cervical histologic high-grade squamous intraepithelial lesions (HSIL): results from a randomized phase Ⅲ global study
- 高蜀君,隋龙.子宫颈高级别鳞状上皮内病变的规范化处理及随访[J].中国实用妇科与产科杂志. 2020,36(07):604-608.
About APL-1702(Cevira®)
APL-1702(Cevira ® ) is a breakthrough photodynamic drug-device combination product that is being developed for non-surgical treatment of high-grade precancerous lesions of the cervix. Cevira ® holds the potential to serve the high unmet medical need for non-invasive treatment options for patients with HSIL in an outpatient setting, especially for young women of reproductive age. Asieris Pharmaceuticals entered into a license agreement with Photocure ASA (Photocure, PHO: OSE) to obtain the worldwide development and commercialization of Cevira ® in July 2019. Cevira ® is a registered trademark of Photocure ASA, based in Oslo, Norway.
14 Likes
Gitt det man vet om ambisjonene/behovet Kina har for å gjøre noe med fertilitetsutfordringene, så er det interessant å se hva slags terreng Asieris med ambassadører som dette beveger seg i. For min del tilsier det at PHO vil kunne oppleve at Asieris sikrer seg globale rettigheter (noe de har gjort tidligere) og/eller at selskapet rett og slett kjøpes opp. Kina er også et sted der ting kan gå relativt raskt om først en “løsning” på et problem blir tilgjengelig.
7 Likes
(Asieris har allerede kjøpt de globale rettighetene for produktet.)
1 Like
Trodde de kun hadde Asia/Kina, takk for oppklaring.
utdrag:
“The benefit of a therapy like this is that it is low risk, it’s office-based, it doesn’t need anesthesia, had very limited treatment-related adverse events that were quite manageable, and doesn’t require any anatomic disruption of the cervix, which could have an impact on fertility, cervical stenosis, and pelvic pain,” noted SGO discussant Kristin Bixel, MD, of the Ohio State University Comprehensive Cancer Center in Columbus.
However, Bixel questioned whether placebo was an appropriate control arm, and noted that an excisional procedure or ablation would be appropriate for patients over the age of 25. She also said long-term outcomes with APL-1702, as well as patient experience, compared with other appropriate or indicated procedures should be evaluated.
“Additionally, it would be important to consider the cost of this device, especially if retreatment is frequently indicated,” she added.
Wang explained that while low-grade squamous intraepithelial lesions (LSIL) usually resolves spontaneously, guidelines for cervical cancer screening generally recommend medical treatment for women with HSIL – surgical treatments that could result in complications for women of reproductive age.
6 Likes
Wang and colleagues also conducted analyses of 216 HSIL patients in the APL-1702 group with 6-month efficacy data who entered the open-label extension of the study.
Based on results from the extension population, Wang reported that responses with APL-1702 were durable:
- Of 102 patients who responded at 6 months, 54.9% maintained response until 12 months after first treatment
- 40% of patients who had LSIL histology and non-clearance of baseline HPV at 6 months became responders at 12 months
- The overall response rate at 12 months was 44.4% – 58.3% of patients had maintained response and 41.7% were new responders
Wang also noted that among the entire study population, the proportion of patients treated with APL-1702 who were HPV-positive at baseline fell to 82.1% at 3 months, 64.8% at 6 months, and 41.4% at 12 months. There was a trend of increasing HPV clearance over time, and up to 12 months.
3 Likes
Canadian Health Authorities approve updated and expanded label for Cysview
Oslo, Norway, March 22, 2024: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the reception of the Note of Compliance from Health Canada this week, approving the updated Product Monograph for Cysview® in Canada.
The updated indication now covers non-muscle invasive bladder cancer in general, including detection of carcinoma in situ (CIS), a very aggressive form of bladder tumor that is difficult to detect because of its flat shape.
The indication now reads:
“CYSVIEW (hexaminolevulinate hydrochloride) is indicated for:
As an adjunct to white-light cystoscopy in the diagnosis and follow up of non-muscle invasive bladder cancer, including carcinoma in situ (CIS), in patients with known or suspected bladder cancer to increase tumor detection.”
In addition, there has been a confirmation of the safe use of Cysview, by update of the safety sections of the Product Monograph, and a clarification that no safety risk has been identified by repeated use of Cysview.
10 Likes
8 Likes
Norsk:
Ny publikasjon: Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy
Pressemelding – Oslo, Norge, 28. mars 2024: Photocure ASA, The Bladder Cancer Company, kunngjør publiseringen av studien «Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy: Insights from a Multicenter Registry» i tidsskriftet Cancers denne uka. Denne studien tar sikte på å evaluere heterogenitet i egenskaper ved blått lys cystoskopi (BLC®) for påvisning av ondartede lesjoner blant ulike raser med ikke-muskelinvasiv blærekreft (NMIBC).
Studieforfatteren Sia Daneshmand, MD og deltakerne i BLC med Cysview Study Group samlet inn klinikopatologisk informasjon fra voksne pasienter som gjennomgikk transurethral reseksjon av blæretumor (TURBT) eller biopsi som ble registrert i det multiinstitusjonelle BLC Cysview-registeret mellom april 2014 og februar 2021. Det primære resultatet var påvisning av enhver ondartet lesjon ved endelig patologi. Sensitivitet, negative og positive prediktive verdier for påvisning av ondartede lesjoner ble beregnet for BLC, hvitt lys cystoskopi (WLC) og kombinasjonen av begge modaliteter.
Totalt ble det identifisert 2379 separate prøver fra 1292 pasienter, hvorav 1095 (85 %) var hvite/kaukasiske, 96 (7 %) svarte/afroamerikanere, 51 (4 %) asiatiske og 50 (4 %) latinamerikanske. Sensitiviteten til WLC, BLC og kombinasjonen av begge for enhver malign lesjon var henholdsvis 88,7 %, 95,8 % og 99 % i den totale kohorten (P<0,001). BLC-sensitivitet vs. WLC var mest signifikant uttalt i den asiatiske befolkningen (96 % vs 78 %, P<0,001). I alle raser var sensitiviteten til BLC signifikant høyere enn WLC for påvisning av CIS (P<0,001). I tillegg økte tillegget av BLC til standard WLC deteksjonsraten med 10 % for enhver ondartet lesjon i hele kohorten. Denne frekvensen økte til 18 % hos asiatiske pasienter. Positiv prediktiv verdi av BLC var også den høyeste i asiatisk befolkning (94,4 %).
Forfatterne konkluderer med at uavhengig av rase, økte BLC påvisningen av blærekreft når kombinert med WLC. Forskjellen var imidlertid mer uttalt hos asiatiske pasienter: «Vår studie viste at uavhengig av rase, øker BLC oppdagelsen av blærekreft når det kombineres med WLC. Disse resultatene kan identifisere forskjeller i grupper som vil føre til forbedret behandling av undertjente minoritetspopulasjoner. Ytterligere forskning er berettiget for å forstå den underliggende etiologien til disse observasjonene som til slutt kan endre tolkningen av lesjoner oppdaget av BLC,” sa Dr. Daneshmand.
9 Likes